Pikkelysömör: vizsgálatok itt: Argentína
5 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Rosario
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 3. fázisTaking peopleLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Where
- Autonomous City of Buenos Aires, Buenos Aires, C.a.b.a., CABA, Ciudad Autonoma Buenos Aires, Ciudad Autónoma Buenos Aires, Córdoba, Mendoza
- Életkor
- 40 év and over
- People
- 3040 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Buenos Aires, Ciudad Autonoma de Buenos Aires, SAN M. de Tucuman
- Életkor
- 12 év to 17 év
- People
- 366 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00 - 3. fázisTaking peopleA Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Buenos Aires, CABA, Ciudad Autonoma de Buenos Aires, Córdoba
- Életkor
- 4 év to 18 év
- People
- 153 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00 - No phaseTaking peopleAn Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
- Where
- Quilmes, Río Cuarto, San Isidro
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- AbbVie
See details and how to joinNCT06764693